Legal & General Group Plc Invests $2.73 Million in Inspire Medical Systems, Inc. $INSP

Legal & General Group Plc bought a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) during the 2nd quarter, Holdings Channel reports. The fund bought 61,236 shares of the company’s stock, valued at approximately $2,732,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Alberta Investment Management Corp bought a new stake in Inspire Medical Systems in the second quarter valued at $5,483,000. Bank of Nova Scotia raised its holdings in Inspire Medical Systems by 49.8% in the 1st quarter. Bank of Nova Scotia now owns 60,000 shares of the company’s stock worth $3,095,000 after purchasing an additional 19,958 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Inspire Medical Systems in the 2nd quarter worth about $820,000. Assenagon Asset Management S.A. lifted its position in shares of Inspire Medical Systems by 66.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock worth $38,561,000 after purchasing an additional 344,221 shares during the period. Finally, Empowered Funds LLC bought a new stake in shares of Inspire Medical Systems during the 1st quarter valued at about $1,799,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Price Performance

Shares of Inspire Medical Systems stock opened at $62.99 on Friday. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of 13.63, a PEG ratio of 4.79 and a beta of 0.70. The company has a 50-day moving average of $55.05 and a 200 day moving average of $52.43.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. Inspire Medical Systems’s quarterly revenue was down 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 EPS for the current year.

Insider Activity at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider directly owned 18,985 shares of the company’s stock, valued at $1,130,556.75. The trade was a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on INSP shares. JPMorgan Chase & Co. boosted their price target on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Bank of America lowered shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective for the company. in a report on Friday, May 22nd. Weiss Ratings downgraded Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Robert W. Baird increased their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, Stifel Nicolaus set a $75.00 target price on Inspire Medical Systems in a research note on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $66.19.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.